irazu-oncology-logo.png
Irazú Oncology Secures Bridge Funding, Expands Leadership Team and Facilities
March 04, 2025 08:30 ET | Irazu Oncology
Dr. Mayukh Das, joined Irazú as CMO, bringing extensive oncology drug development experience from leadership roles at global pharmaceutical companies.
immunocore-logo-2018
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
February 26, 2025 07:00 ET | Immunocore Holdings plc
KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials...
22157.jpg
Immunotherapy Drugs Market Research 2024-2030 with Analyst Recommendations - Adoption of AI in Drug Discovery and Combination Therapies
February 26, 2025 06:42 ET | Research and Markets
Dublin, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The "Immunotherapy Drugs Market (2025 Edition): Analysis By Indication (Cancer, Autoimmune & Inflammatory Diseases, Other Indications), By Drug Type, By...
medicenna.jpg
Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update
February 25, 2025 07:00 ET | Medicenna Therapeutics Corp.
MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity MDNA11 has shown durable single agent activity, with a...
TMR-Logo.png
Pancreatic Cancer Treatment Market to Surge to USD 10.2 Billion by 2034, Driven by Advancements in Immunotherapies and Early Diagnostics – Transparency Market Research
February 06, 2025 11:00 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. - , Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Pancreatic Cancer Treatment Market is set for remarkable growth, projected to reach...
CytoMed logo.png
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
February 06, 2025 07:20 ET | CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders from the Chairman of the Company’s Board...
medicenna.jpg
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
February 05, 2025 07:00 ET | Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
TMR-Logo.png
Non-Muscle Invasive Bladder Cancer Market Poised for $21.1 Bn Surge by 2034, Driven by Expanding Therapeutic Innovations | Transparency Market Research
January 31, 2025 09:45 ET | Transparency Market Research
Wilmington, Delaware, Transparency Market Research Inc. –, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The global non-muscle invasive bladder cancer (NMIBC) market (非筋肉浸潤性膀胱癌市場), valued at US$ 2.6 billion in...
CalidiBiotherapeutics-Logo@2x.jpg
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
January 29, 2025 08:00 ET | Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Cancer Immunotherapy Market
Cancer Immunotherapy Market, Valued at $125.68 Billion in 2025, Sees $194.64 Billion Opportunity by 2029 - Dominated by Amgen, AstraZeneca, Roche, Bayer, and Eli Lilly
January 28, 2025 11:29 ET | Research and Markets
Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report 2025" has been added to ResearchAndMarkets.com's offering.This Cancer Immunotherapy market report covers market...